Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ASAP3
, an Arf GTPase-activating protein previously called DDEFL1 and ACAP4, has been implicated in the pathogenesis of hepatocellular carcinoma. We have examined in vitro and in vivo functions of
ASAP3
and compared it to the related Arf GAP ASAP1 that has also been implicated in oncogenesis.
ASAP3
was biochemically similar to ASAP1: the pleckstrin homology domain affected function of the catalytic domain by more than 100-fold; catalysis was stimulated by phosphatidylinositol 4,5-bisphosphate; and Arf1, Arf5, and Arf6 were used as substrates in vitro. Like ASAP1,
ASAP3
associated with focal adhesions and circular dorsal ruffles. Different than ASAP1,
ASAP3
did not localize to invadopodia or podosomes. Cells, derived from a mammary carcinoma and from a
glioblastoma
, with reduced
ASAP3
expression had fewer actin stress fiber, reduced levels of phosphomyosin, and migrated more slowly than control cells. Reducing
ASAP3
expression also slowed invasion of mammary carcinoma cells. In contrast, reduction of ASAP1 expression had no effect on migration or invasion. We propose that
ASAP3
functions nonredundantly with ASAP1 to control cell movement and may have a role in cancer cell invasion. In comparing ASAP1 and
ASAP3
, we also found that invadopodia are dispensable for the invasive behavior of cells derived from a mammary carcinoma.
...
PMID:ASAP3 is a focal adhesion-associated Arf GAP that functions in cell migration and invasion. 1840 Jul 62